Prediction of In Vivo Clearance and Associated Variability of CYP2C19 Substrates by Genotypes in Populations Utilizing a Pharmacogenetics-Based Mechanistic Model
Open Access
- 1 June 2015
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 43 (6) , 870-883
Abstract
It is important to examine the cytochrome P450 2C19 (CYP2C19) genetic contribution to drug disposition and responses of CYP2C19 substrates during drug development. Design of such clinical trials requires projection of genotype-dependent in vivo clearance and associated variabilities of the investigational drug, which is not generally available during early stages of drug development, but is essential for CYP2C19 substrates with multiple clearance pathways. This study evaluated the utility of pharmacogenetics-based mechanistic modeling in predicting such parameters. Hepatic CYP2C19 activity and variability within genotypes were derived from in vitro S-mephenytoin metabolic activity in genotyped human liver microsomes (N = 128). These data were then used in mechanistic models to predict genotype-dependent disposition of CYP2C19 substrates (i.e., S-mephenytoin, citalopram, pantoprazole, and voriconazole) by incorporating in vivo clearance or pharmacokinetics of wild-type subjects and parameters of other clearance pathways. Relative to the wild-type, the CYP2C19 abundance (coefficient of variation percentage) in CYP2C19*17/*17, *1/*17, *1/*1, *17/null, *1/null, and null/null microsomes was estimated as 1.85 (117%), 1.79 (155%), 1.00 (138%), 0.83 (80%), 0.38 (130%), and 0 (0%), respectively. The subsequent modeling and simulations predicted, within 2-fold of the observed, the means and variabilities of urinary S/R-mephenytoin ratio (36 of 37 genetic groups), the oral clearance of citalopram (9 of 9 genetic groups) and pantoprazole (6 of 6 genetic groups), and voriconazole oral clearance (4 of 4 genetic groups). Thus, relative CYP2C19 genotype-dependent hepatic activity and variability were quantified in vitro and used in a mechanistic model to predict pharmacokinetic variability, thus allowing the design of pharmacogenetics and drug-drug interaction trials for CYP2C19 substrates.Keywords
This publication has 54 references indexed in Scilit:
- CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteersEuropean Journal of Clinical Pharmacology, 2012
- Functional Evaluation of Genetic and Environmental Regulators of P450 mRNA LevelsPLOS ONE, 2011
- Bioavailability Considerations in Evaluating Drug‐Drug Interactions Using the Population Pharmacokinetic ApproachThe Journal of Clinical Pharmacology, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel TherapyClinical Pharmacology & Therapeutics, 2011
- Evaluation of the Effects of 20 Nonsynonymous Single Nucleotide Polymorphisms of CYP2C19 on S-Mephenytoin 4′-Hydroxylation and Omeprazole 5′-HydroxylationDrug Metabolism and Disposition, 2011
- Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug–drug interactions: usingin vitrodata as an aid to assess study powerPharmaceutical Statistics, 2009
- The use of mechanistic DM‐PK‐PD modelling to assess the power of pharmacogenetic studies –CYP2C9and warfarin as an exampleBritish Journal of Clinical Pharmacology, 2007
- Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4′‐hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometryRapid Communications in Mass Spectrometry, 2006
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among EthiopiansPharmacogenetics, 1996